Investing in Public Cannabis Companies

Green Thumb Industries Reports $1.1 Billion in Revenue in 2023, a 4% Increase From Prior Year

The multistate cannabis operator and owner of RISE Dispensaries, which opened 15 new stores in 2023, reported its fourth quarter and 2023 financial results.

Verano Hits Record Revenue of $938 Million in 2023

The company also increased 2023 net cash provided by operating activities by 16% to $110 million and generated $73 million in free cash flow.

Trulieve Reports Fourth Quarter and Full Year 2023 Results Highlighting Year End Momentum and Cash Generation

Trulieve Cannabis Corp. today announced its results for the fourth quarter and full year ended Dec. 31, 2023. The company summarized highlights of 2023 including opening 17 dispensaries in 2023, increasing retail footprint to 192 retail locations nationwide.

The Cannabist Co. Announces Debt Repurchase Agreement

The company’s agreement aims to reduce leverage by up to $25 million and decrease its interest expense.

Curaleaf Commences TSX Trading Dec. 14

Executives from the multistate cannabis operator rang the opening bell Thursday in Toronto following a delisting of shares from the CSE.

UPDATE: Cboe Canada Could Be Verano’s Launching Pad to List on US Exchanges

Verano Chief Investment Officer Aaron Miles details the Chicago-based cannabis company’s move from CSE to Canada’s NEO Exchange.

Columbia Care to Voluntarily Delist Common Shares From CSE

While the cannabis company is delisting from the Canadian Securities Exchange, it will continue trading on the Cboe Canada.

Verano CEO Says 2023 Will Be ‘Inflection Point’ for Cannabis Industry

As smaller operators struggle to weather the industry downturn, George Archos forecasts favorable M&A deals in attractive markets.

Persisting Toward a Public Listing

After going public on the Canadian Securities Exchange in 2018, the founders of cannabis cultivation company Grown Rogue recall the challenges they faced and lessons they learned in the process.

Will Biden’s Order to Review Cannabis’s CSA Scheduling Impact Publicly Traded Cannabis Companies?

Cannabis experts and publicly traded operators weigh in on the announcement’s effects on stocks last month, as well what the future could hold if cannabis is either descheduled or rescheduled from its current Schedule I status in the Controlled Substances Act.

Year-to-Date, Cannabis REITs Provide Key Source of Financing for Businesses

In 2022, falling equity prices have had a chilling effect on capital raises, particularly on large equity issues, which have been confined to non-plant-touching sectors.

Agrios Global Sues Former Directors Over $30M Cannabis Facility

The lawsuit in Mason County, Wash., alleges the former board chairman and CEO breached fiduciary duties by unlawfully taking the property and business.

Page 1 of 5

Next Page